With these trends in view, let’s look at the 7 most undervalued biotech stocks to invest in.

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors�reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

The 10 most undervalued stocks from our Best Companies to Own list as of Feb. 27, 2025, were: Here’s a little bit about why ...

The four-pronged strategy begins with the acquisition of GSK's oncology portfolio, which includes all of its marketed products and late-stage candidates, for $14.5 billion, with a further $1.5 ...

The oncology therapy landscape is rapidly evolving, with immune checkpoint inhibitors reshaping cancer treatment by leveraging the body's own immune system to combat tumors. As the immune checkpoint ...

Most of this spent is out of the pocket. By providing a big portfolio of 140 products with a relative low price, GSK is winning the game of "volume" in the market. This large portfolio also gives ...

SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved ...

Pfizer's strong fundamentals, impressive R&D achievements, and undervalued metrics underscore its defensive appeal and growth ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Learn more about whether Exact Sciences Corporation or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ ...

At Diageo, leadership is not just about titles it’s about impact, innovation, and inclusivity. As a global leader in the beverage industry, Diageo has long championed gender diversity, ensuring that ...